Treating Epilepsy with Natural Products: Nonsense or Possibility?

MALANÍK, Milan, Marie ČULENOVÁ, Alice SYCHROVÁ, Adrianna SKIBA, Krystyna SKALICKA-WOZNIAK and Karel ŠMEJKAL. Treating Epilepsy with Natural Products: Nonsense or Possibility? PHARMACEUTICALS. BASEL: MDPI, 2023, vol. 16, No 8, p. 1-22. ISSN 1424-8247. Available from: https://dx.doi.org/10.3390/ph16081061.

Basic information

• Original name: Treating Epilepsy with Natural Products: Nonsense or Possibility?
• Authors: MALANÍK, Milan (203 Czech Republic, guarantor, belonging to the institution), Marie ČULENOVÁ (203 Czech Republic, belonging to the institution), Alice SYCHROVÁ (203 Czech Republic, belonging to the institution), Adrianna SKIBA, Krystyna SKALICKA-WOZNIAK and Karel ŠMEJKAL (203 Czech Republic, belonging to the institution).
• Edition: PHARMACEUTICALS, BASEL, MDPI, 2023, 1424-8247.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30104 Pharmacology and pharmacy
• Country of publisher: Switzerland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 4.600 in 2022
• RIV identification code: RIV/00216224:14160/23:00132229
• Organization unit: Faculty of Pharmacy
• Doi: http://dx.doi.org/10.3390/ph16081061
• UT WoS: 001056447600001
• Keywords in English: epilepsy; anticonvulsant; natural products; GABA; AMPA; NMDA
• Tags: rivok, ÚPL
• Tags: International impact, Reviewed

Abstract

Epilepsy is a neurological disease characterized by recurrent seizures that can lead to uncontrollable muscle twitching, changes in sensitivity to sensory perceptions, and disorders of consciousness. Although modern medicine has effective antiepileptic drugs, the need for accessible and cost-effective medication is urgent, and products derived from plants could offer a solution. For this review, we have focused on natural compounds that have shown anticonvulsant activity in in vivo models of epilepsy at relevant doses. In some cases, the effects have been confirmed by clinical data. The results of our search are summarized in tables according to their molecular targets. We have critically evaluated the data we present, identified the most promising therapeutic candidates, and discussed these in the text. Their perspectives are supported by both pharmacokinetic properties and potential interactions. This review is intended to serve as a basis for future research into epilepsy and related disorders.